FDA
August 1st, 2002
BY PHILIP FINE
The US Food and Drug Administration (FDA) is updating
inspection rules for pharmaceutical products in an effort to improve the
safety and efficiency of production and restore consumer and manufacturer
confidence in the agency.
The planned revision of the current "good manufacturing practice
Program" comes in the wake of several recent incidents that have shaken
confidence in
drugs manufacture in the US.
They include the recall of soft tissue grafts
that may have been contaminated, by a US tissue bank, agreement by
Schering-Plough ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.